Soligenix, Inc. (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, ...

Large granular lymphocytic leukemias (LGLLs) are a heterogeneous group of rare chronic lymphoproliferative disorders characterized by the clonal ...

making it the first and only US IND for an in vivo CAR-T therapy. UBVV-111 is in a Phase I clinical trial (INVICTA-1) in the US for chronic lymphocytic leukaemia and diffuse large B-cell lymphoma ...

T-cell skin lymphomas are more common than B-cell skin lymphomas. T-Cell Skin Lymphoma Cutaneous T-cell lymphoma (CTCL) occurs when a mutation causes the cell to divide too quickly and stay alive too ...

- Marks Amneal’s fourth 505(b)(2) injectable product launch in the last year BRIDGEWATER, N.J., April 01, 2025--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc ...

1Institutes of Biology and Medical Sciences, MOE Key Laboratory of Geriatric Diseases and Immunology, Jiangsu Key Laboratory of Infection and Immunity, Suzhou Medical College of Soochow University, ...

Wojciech Jurczak, MD, PhD, discusses the future of B-cell lymphoma therapy, with a focus on Bruton's tyrosine kinase inhibitors and degraders. Wojciech Jurczak, MD, PhD, head of the department of ...

T-cell lymphomas include a number of subtypes of T cell-derived non-Hodgkins's lymphoma, including cutaneous T-cell lymphoma ... for tumor expansion and survival, representing a new and promising ...

with 6-month overall survival at 87.5% and 1-year overall survival at 75% for patients diagnosed before CAR T-cell therapy. The safety profile showed 80% of patients experiencing grade 1-2 ...